BTIG Reiterates Buy on Praxis Precision Medicine, Maintains $810 Price Target
Praxis Precision Medicines Inc PRAX
$307.83
▲ +0.03%
(+$0.08)
🎢 High Beta
📅 Earnings This Week
Open
$308.74
Prev Close
$307.75
Day Range
$293.22 – $310.15
52W Range
$37.19 – $366.52
Market Cap
$8.58B
Beta
2.81
EPS (TTM)
$-13.37
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2020-10-16 |
| Shares Out. | 27,880,000 |
| Website | praxismedicines.com/ ↗ |
| Phone | 16173008460 |
| Employees | 10,998 |
| Net Income | -$92.6M |
| Free Cash Flow | -$282.3M |
| Total Assets | $1.46B |
| Total Liabilities | $50.2M |
| Equity | $1.41B |
About Praxis Precision Medicines Inc
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.
Praxis Precision Medicines Inc is a publicly traded company under the ticker symbol PRAX on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
24 analysts (2026-07-01)